Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
15 Février 2025 - 12:09AM
Edgar (US Regulatory)
EXHIBIT 99.1
JOINT FILING AGREEMENT
In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of 4D Molecular Therapeutics, Inc. and further agree that this agreement be included as an exhibit to such filing. Each party to the agreement expressly authorizes each other party to file on its behalf any and all amendments to such statement. Each party to this agreement agrees that this joint filing agreement may be signed in counterparts.
In evidence whereof, the undersigned have caused this Agreement to be executed on their behalf this 14th day of February, 2025.
| |
Venrock Healthcare Capital Partners III, L.P.
By:
VHCP Management III, LLC
Its:
General Partner
By:
/s/ Sherman G. Souther
Name: Sherman G. Souther
Its: Authorized Signatory
| Venrock Healthcare Capital Partners EG, L.P.
By:
VHCP Management EG, LLC
Its:
General Partner
By:
/s/ Sherman G. Souther
Name: Sherman G. Souther
Its: Authorized Signatory
|
VHCP Co-Investment Holdings III, LLC
By:
VHCP Management III, LLC
Its:
Manager
By:
/s/ Sherman G. Souther
Name: Sherman G. Souther
Its: Authorized Signatory
|
|
VHCP Management III, LLC
By:
/s/ Sherman G. Souther
Name: Sherman G. Souther
Its: Authorized Signatory
| VHCP Management EG, LLC
By:
/s/ Sherman G. Souther
Name: Sherman G. Souther
Its: Authorized Signatory
|
Nimish Shah
/s/ Sherman G. Souther
Sherman G. Souther, Attorney-in-fact
Bong Koh
/s/ Sherman G. Souther
Sherman G. Souther, Attorney-in-fact
|
|
4D Molecular Therapeutics (NASDAQ:FDMT)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025
4D Molecular Therapeutics (NASDAQ:FDMT)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025
